These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 37583422)

  • 21. Efficacy and safety comparison of PD-1 inhibitors
    Yang G; Sun H; Sun N; Huang W; Wang Z; Zhang H; Liu C
    J Thorac Dis; 2022 Dec; 14(12):4925-4937. PubMed ID: 36647464
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness and safety of PD-1/PD-L1 or CTLA4 inhibitors combined with chemotherapy as a first-line treatment for lung cancer: A meta-analysis.
    Shen K; Cui J; Wei Y; Chen X; Liu G; Gao X; Li W; Lu H; Zhan P; Lv T; Lin D
    J Thorac Dis; 2018 Dec; 10(12):6636-6652. PubMed ID: 30746209
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A retrospective real-world experience of immunotherapy in patients with extensive stage small-cell lung cancer.
    Qiu G; Wang F; Xie X; Liu T; Zeng C; Chen Z; Zhou M; Deng H; Yang Y; Lin X; Xie Z; Sun G; Zhou C; Liu M
    Cancer Med; 2023 Jul; 12(14):14881-14891. PubMed ID: 37462138
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The efficacy and safety of immune-checkpoint inhibitors plus chemotherapy versus chemotherapy for non-small cell lung cancer: An updated systematic review and meta-analysis.
    Kang J; Zhang J; Tian Z; Xu Y; Li J; Li M
    PLoS One; 2024; 19(2):e0276318. PubMed ID: 38319920
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of PD-1/PD-L1 Inhibitors versus Chemotherapy in Lung Cancer with Brain Metastases: A Systematic Review and Meta-Analysis.
    Yang X; Zeng Y; Tan Q; Huang Z; Jia J; Jiang G
    J Immunol Res; 2022; 2022():4518898. PubMed ID: 35637793
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of amrubicin-based regimen used as first-line for extensive-disease small-cell lung cancer: A meta-analysis of randomized controlled trials.
    Liu CQ; Tian D; Wang N; Meng XP; Yang JD; Li HW; Zhao N; Zhao S; Liao F; Cui Y
    Asia Pac J Clin Oncol; 2018 Apr; 14(2):e81-e87. PubMed ID: 29071806
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association Between Efficacy of Immune Checkpoint Inhibitors and Sex: An Updated Meta-Analysis on 21 Trials and 12,675 Non-Small Cell Lung Cancer Patients.
    Xue C; Zheng S; Dong H; Lu X; Zhang X; Zhang J; Li J; Cui H
    Front Oncol; 2021; 11():627016. PubMed ID: 34513654
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Small cell lung cancer patients treated with immune checkpoint inhibitor: a systematic literature review of treatment efficacy, safety and quality of life.
    Korde R; Veluswamy R; Allaire JC; Barnes G
    Curr Med Res Opin; 2022 Aug; 38(8):1361-1368. PubMed ID: 35575164
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and Safety of First-Line Immunotherapy in Combination with Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
    Wang BC; Xiao BY; Li PC; Kuang BH; Chen WB; Li PD; Lin GH; Liu Q
    J Oncol; 2020; 2020():2368164. PubMed ID: 33061969
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive Efficacy of Blood-Based Tumor Mutation Burden Assay for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Zhang N; Zhang J; Wang G; He X; Mi Y; Cao Y; Yu X
    Front Oncol; 2022; 12():795933. PubMed ID: 35223476
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PD-1/PD-L1 immune checkpoint inhibitors in metastatic triple-negative breast cancer: a systematic review and meta-analysis.
    Yu Y; Jin X; Zhu X; Xu Y; Si W; Zhao J
    Front Immunol; 2023; 14():1206689. PubMed ID: 37377959
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma.
    Sun M; Ji H; Xu N; Jiang P; Qu T; Li Y
    BMC Cancer; 2022 Jul; 22(1):762. PubMed ID: 35831785
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of immune checkpoint inhibitors (ICIs) in extensive-stage small cell lung cancer (SCLC).
    Ma X; Wang S; Zhang Y; Wei H; Yu J
    J Cancer Res Clin Oncol; 2021 Feb; 147(2):593-606. PubMed ID: 32852633
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of immune checkpoint inhibitors at different treatment time periods on prognosis of patients with extensive-stage small-cell lung cancer.
    Mi S; Yang Y; Liu X; Tang S; Liang N; Sun J; Liu C; Ren Q; Lu J; Hu P; Zhang J
    Clin Transl Oncol; 2024 Sep; 26(9):2339-2350. PubMed ID: 38598001
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of immune checkpoint inhibitors with or without radiotherapy in metastatic non-small cell lung cancer: A systematic review and meta-analysis.
    Liu Z; Xu T; Chang P; Fu W; Wei J; Xia C; Wang Q; Li M; Pu X; Huang F; Ge C; Gao Y; Gong S; Liu C; Dong L
    Front Pharmacol; 2023; 14():1064227. PubMed ID: 36762107
    [No Abstract]   [Full Text] [Related]  

  • 36. Retrospective study of the combination of TP and PF regimens with or without immune checkpoint inhibitors for the first-line treatment of locally advanced or advanced esophageal squamous cell carcinoma.
    Zhang Z; Yang L; Wang D; Ruan Y; Zhang J; Zhao L; Yang L; Lou C
    Ther Adv Med Oncol; 2023; 15():17588359231169981. PubMed ID: 37188111
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of immune checkpoint inhibitors in EGFR-Mutant NSCLC patients with EGFR-TKI resistance: A systematic review and meta-analysis.
    Qian X; Guo X; Li T; Hu W; Zhang L; Wu C; Ye F
    Front Pharmacol; 2022; 13():926890. PubMed ID: 36071838
    [No Abstract]   [Full Text] [Related]  

  • 38. Checkpoint inhibitors as dual immunotherapy in advanced non-small cell lung cancer: a meta-analysis.
    Alifu M; Tao M; Chen X; Chen J; Tang K; Tang Y
    Front Oncol; 2023; 13():1146905. PubMed ID: 37397392
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment- and immune-related adverse events of immune checkpoint inhibitors in esophageal or gastroesophageal junction cancer: A network meta-analysis of randomized controlled trials.
    Zheng J; Huang B; Xiao L; Wu M; Li J
    Front Oncol; 2022; 12():821626. PubMed ID: 36568203
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The efficacy and safety of immune checkpoint inhibitor in patients with relapsed small-cell lung cancer: A systematic review and meta-analysis.
    Xu Y; Chen M; Ding Y; Guo F; Chen M; Lu T
    J Clin Pharm Ther; 2022 Apr; 47(4):421-429. PubMed ID: 34734431
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.